There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.

WHO Warns Against Fake Cancer Drugs

The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.

In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.

About The Cancer Medicine

DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.

The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.

Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories

WHO Identified The Counterfeit Batch Numbers

WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.

The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.

The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.

It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.

Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety

WHO issued precautionary measures to avoid purchasing falsified medications:

• Healthcare professionals should report suspected falsified products, unexpected side effects, or lack of therapeutic effects to their national regulatory authorities and health and disease bodies.

• WHO has advised patients and caregivers to obtain medicines only from licensed pharmacies and authorised healthcare providers.

• Patients must also inspect packaging carefully and seek medical advice if they notice any unusual appearance or suspect their medication may not be genuine.

• The global health organisation stressed that people should not use any product suspected to be falsified and should report it to health authorities immediately.

Falsified Drugs Are A Growing Global Threat

The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.

In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.

The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.

Indian scientists from ICMR-NIRWoH and IIT Bombay have developed "placenta-on-chip" platform that mimics key functions of the human placenta. The indigenous innovation could transform maternal and fetal health studies while reducing dependence on animal testing.

Indian Scientists Develop Placenta-On-Chip

In a major breakthrough for pregnancy and fetal health research, Indian scientists have developed an indigenous “placenta-on-chip" platform that successfully mirrors several important functions of the human placenta.

According to the journal Biofabrication, the platform, developed by researchers from the ICMR-National Institute for Research on Women's Health (ICMR-NIRWoH) in collaboration with IIT Bombay, will equip scientists with a new tool to study pregnancy in depth, understand complications, and evaluate the safety of medicines during pregnancy.

Also read: WHO Unveils Global Action Plan To Combat Rising Fungal Infections And Drug Resistance

Significance Of Placenta

The placenta is a temporary organ that develops during pregnancy and acts as the lifeline between the mother and the unborn baby.

It provides unborn babies with oxygen and nutrients, eliminates waste products, produces hormones essential for pregnancy, and serves as a protective barrier for the baby.

Despite its vital role in the development of a healthy baby, the placenta remains one of the least understood human organs because its research during pregnancy is both ethically and technically challenging.

How Will Placenta-On-Chip Help Researchers?

The placenta-on-chip operates like a laboratory platform, recreating the interface between the mother and the fetus using living human cells. It reproduces several essential functions of the placenta, including:

• Production of pregnancy hormones

• Transfer of nutrients

• Removal of waste products including urea

• A selective barrier function that regulates what reaches the fetus

Researchers also demonstrated that the platform could simulate hyperglycaemic conditions similar to gestational diabetes, allowing scientists to study how pregnancy-related diseases affect placental function.

The placenta-on-chip platform could significantly improve research into pregnancy complications like:

• Gestational diabetes

• Preeclampsia

• Fetal growth restriction

• Placental disorders

Also read: Cancer Survivorship Beyond Treatment: Why Caregiver Support Must Become A Standard Of Oncology Care

Scientists also believe it could become an important tool for evaluating whether medicines can cross the placental barrier, helping researchers identify drugs that are safer during pregnancy.

Pregnant women are often excluded from clinical drug trials because of ethical concerns, leaving doctors with limited research. Placenta-on-chip may help bridge this gap.

Another major advantage is its potential to reduce dependency on animals for testing. Animal studies do not always accurately reflect how the human placenta functions because placenta structures differ significantly across species. Human cell-based platforms can therefore provide more clinically relevant insights and findings.

The researchers believe the placenta-on-chip could become an important platform for studying maternal-fetal health, testing new therapies, and understanding how various complications develop during pregnancy. The innovation is a step towards establishing clinically safe procedures to tackle pregnancy-related complications.

The technology has the potential to contribute not only to safer pregnancies but also to more reliable, human-based research that could benefit global healthcare. India could progress significantly in biomedical research, influencing and advancing reproductive healthcare systems worldwide.

The World Health Organization (WHO) has released a new global plan, urging countries to improve their response to the growing risk of fungal diseases and antifungal resistance. The health and disease regulatory body warned that the issue has been left unaddressed since a long time despite its serious impact on public health.

WHO Shares Plan To Tackle Fungal Infections & Drug Resistance

According to the WHO, fungal diseases affect more than 300 million people worldwide every year. It also said that they are responsible for serious complications, prolonged hospitalisation, and high mortality, particularly among those with weakened immune systems.

Despite the risks, fungal infections continue to receive far less attention than bacterial or viral diseases. They are also missing from national health strategy planning, particularly in antimicrobial resistance (AMR) plans.

Why Antifungal Resistance Is A Global Concern?

Antifungal resistance happens when fungi grow, resisting medicines used to treat the infections. This makes it harder and sometimes impossible to cure infections.

The WHO said resistance to antifungal drugs is being fueled by:

• Uncontrolled use of antifungal medicines not only in human healthcare but also in agriculture and animal health.

• Excessive environmental exposure to antifungal chemicals continues to accelerate resistance.

• Health experts have repeatedly warned that resistant fungal infections could become a major public health challenge, as the number of people living with conditions that weaken the immune system, including cancer, HIV, diabetes, and other chronic diseases, continues to rise.

• Climate change is also believed to be altering the distribution of certain disease-causing fungi, increasing the risk of outbreaks in new regions.

Also read: The High Cost of Ignoring Fungi: The Hidden Burden of Invasive Fungal Infections

Dr Jean Pierre Nyemazi, Acting Director of WHO's Department of Antimicrobial Resistance said, “The Updated Global Action Plan on AMR approved by the Seventy-ninth World Health Assembly recognized that antifungal resistance is an integral part of the AMR challenge and one we can no longer afford to overlook. This Blueprint gives countries a concrete path forward.”

What Does The WHO Blueprint Outline?

The blueprint to fight fungal infections has been developed with input from more than 150 experts across WHO regions, including specialists in infectious diseases, diagnostics, surveillance, public health and patient advocacy. It builds on the WHO's fungal priority pathogens list released in 2022, which identified the most dangerous fungal pathogens threatening human health.

The guidance outlines four priority areas for countries to strengthen their response. These include:

• Improving public awareness, infection prevention, and antifungal stewardship programmes.

• Expanding access to quality diagnostics and effective antifungal medicines while encouraging research and innovation.

• Strengthening laboratory networks, disease surveillance and outbreak preparedness

• Addressing environmental and agricultural factors contributing to antifungal resistance. Through a One Health approach that recognises the interconnected health of humans, animals and the environment.

The WHO has also identified 12 key areas to help governments prioritise investments and integrate fungal disease surveillance into existing healthcare systems.

WHO officials said fungal diseases continue to be neglected across national health policies despite their growing burden.

Hatim Sati, Technical Officer in WHO's Department of Antimicrobial Resistance, who led the blueprint's development, said, “Fungal disease and antifungal resistance remain an under-addressed priority across national health plans, AMR strategies, and surveillance systems. This Blueprint provides countries with a practical framework to strengthen their response.”